---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021418"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:37:26.565393+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Calidi presents positive preclinical data on CLD-401 at SITC; IND filing expected by end 2026

## Summary
- CLD-401 protected from immune clearance and replicates specifically in tumor cells after systemic administration.
- Systemic CLD-401 achieves tumor IL-15 superagonist levels comparable to localized Anktiva dosing, with minimal systemic exposure.
- IND-enabling studies ongoing; IND submission expected by end of 2026.
- Company actively seeking strategic partnerships to accelerate clinical development.
- Investor day held at SITC featuring experts Dr. Zamarin (Mount Sinai) and Dr. Wrangle (MUSC).

## SEC filing metadata
- accession: 0001493152-25-021418
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315225021418/0001493152-25-021418-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315225021418/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021418
- JSON: https://secwatch.observer/filing/0001493152-25-021418.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021418.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.